Understanding Cellectis’ Share Capital and Voting Rights
When it comes to corporate governance, knowing the details about a company's share capital and voting rights is essential for investors. Cellectis, a prominent biotech firm, has recently disclosed crucial information regarding its financial standing, specifically the number of shares and voting rights available. This transparency allows stakeholders to make informed decisions.
Key Financial Data
Cellectis has revealed significant figures that indicate the overall structure of its share capital. As of the latest report, which focused on the date of May 31, 2025, the total number of shares within the company reached an impressive 100,325,229. This number reflects the company's growth and sustained investment in developing innovative treatments in the biotech sector.
Voting Rights Overview
Equally important are the voting rights associated with these shares. The total number of voting rights on that same date was reported at 89,110,384. This metric is vital for shareholders as it defines their influence over the company’s decisions, including governance and strategic direction.
Market Listing and Trading Information
Cellectis is prominently listed on the Euronext Growth market, making it accessible for investors looking to engage in biotech stock. The ISIN code for Cellectis is FR0010425595. Investors interested in Cellectis on various exchanges can find it listed under Paris: ALCLS and Nasdaq: CLLS, which enhances its visibility and liquidity in the market.
Company Contacts for Investors and Media
Communication is crucial, and Cellectis encourages interaction with both media and investor relations teams for any inquiries. Pascalyne Wilson is the Director of Communications for Cellectis. She can be reached at +33 (0)7 76 99 14 33 or via email at media@cellectis.com. This open line for media helps ensure that journalists and stakeholders have immediate access to the information they need.
High-Level Leadership Contacts
For deeper investor inquiries, Arthur Stril serves as the Chief Financial Officer and Chief Business Officer. Interested parties may contact him for more detailed discussions regarding Cellectis’ financial strategy. He can be reached directly, assisting in fostering a transparent relationship with current and potential investors.
Wrap Up on Voting Rights and Share Capital
The recent announcement by Cellectis regarding its share capital and voting rights provides a clear picture of its current status. This strategic disclosure not only showcases the growth of the company but also impacts investor interest and market perception. Understanding these numbers helps build trust between the company and its stakeholders.
Frequently Asked Questions
What is the total number of shares for Cellectis?
As of May 31, 2025, the total number of shares in Cellectis is 100,325,229.
How many voting rights does Cellectis have?
Cellectis has a total of 89,110,384 voting rights as of the latest report.
On which markets is Cellectis listed?
Cellectis is listed on the Euronext Growth market as well as on Nasdaq under the tickers ALCLS and CLLS.
Who should I contact for more information about Cellectis?
For media inquiries, you can contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or email media@cellectis.com. For investor relations, Arthur Stril is available for more detailed queries.
What is the ISIN code for Cellectis?
The ISIN code for Cellectis is FR0010425595.
